Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 3 distinct examiners across 3 distinct art units, which means each pending application is being evaluated by a different individual in a different technical group. This distribution suggests the 3 pending cases involve diverse biotech or pharmaceutical concepts. Practitioners must prepare for three separate examination styles, as the 3 distinct art units likely apply different standards and prior art searches to the biotechnology-related claims.
DIAMOND, ALAN D is the busiest examiner for the portfolio, managing 1 pending office action. With 3 distinct examiners each handling one case, the workload is evenly distributed across the assigned staff. The presence of 3 distinct art units suggests that the authority's biotechnology innovations are multifaceted, requiring specialized review from several different departments. Counsel should treat each of the 3 pending office actions as an independent effort, as the lack of examiner overlap means that arguments successful in one case may not influence the others.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIAMOND, ALAN D | 1 | 71.5% | +8.5% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18517818 | METHODS AND COMPOSITIONS FOR PRETARGETED IMMUNOTHERAPY | PUTTLITZ, KARL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18517818 | METHODS AND COMPOSITIONS FOR PRETARGETED IMMUNOTHERAPY | PUTTLITZ, KARL J | — |
| 18044747 | RIBITOL TREATMENT | NEAGU, IRINA | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1646 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19265435 | COMPOUNDS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND OTHER DISORDERS | DIAMOND, ALAN D | 3991 | DP | Non-Final OA | — | Pending | Jul 10, 2025 |
| 18517818 | METHODS AND COMPOSITIONS FOR PRETARGETED IMMUNOTHERAPY | PUTTLITZ, KARL J | 1646 | §102§103§112 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18044747 | RIBITOL TREATMENT | NEAGU, IRINA | 1629 | §103§112DP | Non-Final OA | — | Pending | Mar 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Alan D Diamond has the most, with 1 of The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
